{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:39:58Z","timestamp":1782401998152,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Neurofibromatosis type\u00a01 (NF1) is a\u00a0rare autosomal dominant tumor predisposition syndrome with a\u00a0birth prevalence of approximately 1\u00a0in 2000\u20133000 individuals. Management of both benign and malignant tumors arising in individuals with NF1 is demanding and tumors may be difficult to treat. Both standardized and individual surveillance programs are therefore highly important to prevent morbidity and mortality in patients with NF1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The guidelines for the clinical management of NF1 recently proposed by the European Reference Network for Genetic Tumor Risk Syndromes provide the cornerstone of the present surveillance form and were discussed through three rounds of voting and a\u00a0final consensus meeting involving experts from five Austrian and one German clinical NF1 centers for adults and one patient organization representative. Subsequently, 31\u00a0items within 4\u00a0categories were integrated into the proposed surveillance form for Austria. All recommendations, unless otherwise specified, pertain to primarily asymptomatic patients in routine follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recommendations<\/jats:title>\n            <jats:p>At healthcare transition from pediatric to adult surveillance or the initial visit in adulthood, we suggest a\u00a0thorough clinical, laboratory and radiological examination to obtain a\u00a0baseline for future diagnostics. To comply with the general screening recommendations in Austria, we suggest extending the frequency of clinical visits from annual to biennial at 50\u00a0years of age. In cases of clinical dynamics, early follow-up is recommended to facilitate early detection of potential complications. Particular emphasis should be placed on preventive patient education.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-024-02443-0","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T11:04:00Z","timestamp":1726139040000},"page":"487-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neurofibromatosis type\u00a01 adult surveillance form for Austria"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9151-4139","authenticated-orcid":false,"given":"Vincent","family":"Sunder-Plassmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo A.","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Farschtschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hutterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Ladurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claas","family":"R\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welponer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Sophie","family":"Bergmeister-Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"3","key":"2443_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo\u00a0E, Lepp\u00e4virta\u00a0J, Koffert\u00a0A, Suominen\u00a0S, Vahtera\u00a0J, Vahlberg\u00a0T, et\u00a0al. Incidence and Mortality of Neurofibromatosis: A\u00a0Total Population Study in Finland. J\u00a0Investig Dermatology. 2015;135(3):904\u20136.","journal-title":"J Investig Dermatology"},{"issue":"9","key":"2443_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/gim.2017.215","volume":"20","author":"RA Kallionp\u00e4\u00e4","year":"2018","unstructured":"Kallionp\u00e4\u00e4\u00a0RA, Uusitalo\u00a0E, Lepp\u00e4virta\u00a0J, P\u00f6yh\u00f6nen\u00a0M, Peltonen\u00a0S, Peltonen\u00a0J. Prevalence of neurofibromatosis type\u00a01 in the Finnish population. Genet Med. 2018;20(9):1082\u20136.","journal-title":"Genet Med"},{"issue":"11","key":"2443_CR3","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41431-021-00892-z","volume":"29","author":"BAE Dhaenens","year":"2021","unstructured":"Dhaenens\u00a0BAE, Ferner\u00a0RE, Bakker\u00a0A, Nievo\u00a0M, Evans\u00a0DG, Wolkenstein\u00a0P, et\u00a0al. Identifying challenges in neurofibromatosis: a\u00a0modified Delphi procedure. Eur J Hum Genet. 2021;29(11):1625\u201333.","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"2443_CR4","first-page":"S91","volume":"97","author":"B Chetan","year":"2021","unstructured":"Chetan\u00a0B, Meena\u00a0U, Evans\u00a0DG, AeRang\u00a0K, Dimitrios\u00a0M, Clemens\u00a0OH, et\u00a0al. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Neurology. 2021;97(7):S91.","journal-title":"Neurology"},{"issue":"8","key":"2443_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius\u00a0E, Messiaen\u00a0L, Wolkenstein\u00a0P, Pancza\u00a0P, Avery\u00a0RA, Berman\u00a0Y, et\u00a0al. Revised diagnostic criteria for neurofibromatosis type\u00a01 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506\u201313.","journal-title":"Genet Med"},{"issue":"2","key":"2443_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11910-996-0036-5","volume":"6","author":"MT Acosta","year":"2006","unstructured":"Acosta\u00a0MT, Gioia\u00a0GA, Silva\u00a0AJ. Neurofibromatosis type\u00a01: New insights into neurocognitive issues. Curr Neurol Neurosci Rep. 2006;6(2):136\u201343.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"2443_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/bjc.2012.535","volume":"108","author":"OO Seminog","year":"2013","unstructured":"Seminog\u00a0OO, Goldacre\u00a0MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer. 2013;108(1):193\u20138.","journal-title":"Br J Cancer"},{"issue":"17","key":"2443_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo\u00a0E, Rantanen\u00a0M, Kallionp\u00e4\u00e4\u00a0RA, P\u00f6yh\u00f6nen\u00a0M, Lepp\u00e4virta\u00a0J, Yl\u00e4-Outinen\u00a0H, et\u00a0al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type\u00a01. J\u00a0Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2443_CR9","doi-asserted-by":"publisher","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","volume":"4","author":"JP Landry","year":"2021","unstructured":"Landry\u00a0JP, Schertz\u00a0KL, Chiang\u00a0YJ, Bhalla\u00a0AD, Yi\u00a0M, Keung\u00a0EZ, et\u00a0al. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type\u00a01 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021;4(3):e210945. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0945.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2443_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1634\/theoncologist.2010-0181","volume":"17","author":"S Patil","year":"2012","unstructured":"Patil\u00a0S, Chamberlain\u00a0RS. Neoplasms Associated with Germline and Somatic NF1 Gene Mutations. The Oncol. 2012;17(1):101\u201316.","journal-title":"The Oncol"},{"issue":"33","key":"2443_CR11","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.1200\/JCO.2005.01.4886","volume":"23","author":"M Carli","year":"2005","unstructured":"Carli\u00a0M, Ferrari\u00a0A, Mattke\u00a0A, Zanetti\u00a0I, Casanova\u00a0M, Bisogno\u00a0G, et\u00a0al. Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group. J\u00a0Clin Oncol. 2005;23(33):8422\u201330.","journal-title":"J Clin Oncol"},{"issue":"7\u2013S","key":"2443_CR12","first-page":"101","volume":"91","author":"T Foiadelli","year":"2020","unstructured":"Foiadelli\u00a0T, Naso\u00a0M, Licari\u00a0A, Orsini\u00a0A, Magistrali\u00a0M, Trabatti\u00a0C, et\u00a0al. Advanced pharmacological therapies for neurofibromatosis type\u00a01-related tumors. Acta Biomed Atenei Parmensis. 2020;91(7\u2013S):101\u201314.","journal-title":"Acta Biomed Atenei Parmensis"},{"issue":"9","key":"2443_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jmg.2009.075937","volume":"47","author":"VF Mautner","year":"2010","unstructured":"Mautner\u00a0VF, Kluwe\u00a0L, Friedrich\u00a0RE, Roehl\u00a0AC, Bammert\u00a0S, H\u00f6gel\u00a0J, et\u00a0al. Clinical characterisation of 29 neurofibromatosis type-1\u00a0patients with molecularly ascertained 1.4\u202fMb\u00a0type\u20111 NF1 deletions. J\u00a0Med Genet. 2010;47(9):623\u201330.","journal-title":"J Med Genet"},{"key":"2443_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1310-3","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist\u00a0C, Servy\u00a0A, Valeyrie-Allanore\u00a0L, Ferkal\u00a0S, Combemale\u00a0P, Wolkenstein\u00a0P, et\u00a0al. Neurofibromatosis 1\u00a0French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020; https:\/\/doi.org\/10.1186\/s13023-020-1310-3.","journal-title":"Orphanet J Rare Dis"},{"key":"2443_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101818","author":"C Carton","year":"2023","unstructured":"Carton\u00a0C, Evans\u00a0DG, Blanco\u00a0I, Friedrich\u00a0RE, Ferner\u00a0RE, Farschtschi\u00a0S, et\u00a0al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type\u00a01. eClinicalMedicine. 2023; https:\/\/doi.org\/10.1016\/j.eclinm.2022.101818.","journal-title":"eClinicalMedicine"},{"issue":"2","key":"2443_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner\u00a0RE, Huson\u00a0SM, Thomas\u00a0N, Moss\u00a0C, Willshaw\u00a0H, Evans\u00a0DG, et\u00a0al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J\u00a0Med Genet. 2007;44(2):81\u20138.","journal-title":"J Med Genet"},{"issue":"3","key":"2443_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/24694193.2020.1806402","volume":"46","author":"A Goetsch Weisman","year":"2023","unstructured":"Goetsch Weisman\u00a0A, Haws\u00a0T, Lee\u00a0J, Lewis\u00a0AM, Srdanovic\u00a0N, Radtke\u00a0HB. Transition Readiness Assessment in Adolescents and Young Adults with Neurofibromatosis Type\u00a01 (NF1). Compr Child Adolesc Nurs. 2023;46(3):223\u201339.","journal-title":"Compr Child Adolesc Nurs"},{"issue":"2","key":"2443_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen\u00a0R, Jett\u00a0K, Harris\u00a0GJ, Cai\u00a0W, Friedman\u00a0JM, Mautner\u00a0VF. Benign whole body tumor volume is a\u00a0risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type\u00a01. J\u00a0Neurooncol. 2014;116(2):307\u201313.","journal-title":"J Neurooncol"},{"issue":"10","key":"2443_CR19","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00381-020-04718-z","volume":"36","author":"N Winter","year":"2020","unstructured":"Winter\u00a0N, Dohrn\u00a0MF, Wittlinger\u00a0J, Loizides\u00a0A, Gruber\u00a0H, Grimm\u00a0A. Role of high-resolution ultrasound in detection and monitoring of peripheral nerve tumor burden in neurofibromatosis in children. Child\u2019s Nerv Syst. 2020;36(10):2427\u201332.","journal-title":"Child\u2019s Nerv Syst"},{"issue":"9","key":"2443_CR20","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1002\/mgg3.927","volume":"7","author":"H Yl\u00e4-Outinen","year":"2019","unstructured":"Yl\u00e4-Outinen\u00a0H, Loponen\u00a0N, Kallionp\u00e4\u00e4\u00a0RA, Peltonen\u00a0S, Peltonen\u00a0J. Intestinal tumors in neurofibromatosis 1 with special reference to fatal gastrointestinal stromal tumors (GIST). Molec Gen & Gen Med. 2019;7(9):e927.","journal-title":"Molec Gen & Gen Med"},{"issue":"1","key":"2443_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1477-7819-8-14","volume":"8","author":"GN Zografos","year":"2010","unstructured":"Zografos\u00a0GN, Vasiliadis\u00a0GK, Zagouri\u00a0F, Aggeli\u00a0C, Korkolis\u00a0D, Vogiaki\u00a0S, et\u00a0al. Pheochromocytoma associated with neurofibromatosis type\u00a01: concepts and current trends. World J Surg Oncol. 2010;8(1):14.","journal-title":"World J Surg Oncol"},{"issue":"16","key":"2443_CR22","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","volume":"24","author":"S Sharif","year":"2006","unstructured":"Sharif\u00a0S, Ferner\u00a0R, Birch\u00a0JM, Gillespie\u00a0JE, Gattamaneni\u00a0HR, Baser\u00a0ME, et\u00a0al. Second Primary Tumors in Neurofibromatosis 1\u00a0Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy. J\u00a0Clin Oncol. 2006;24(16):2570\u20135.","journal-title":"J Clin Oncol"},{"key":"2443_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","volume":"67","author":"MM Miettinen","year":"2017","unstructured":"Miettinen\u00a0MM, Antonescu\u00a0CR, Fletcher\u00a0CDM, Kim\u00a0A, Lazar\u00a0AJ, Quezado\u00a0MM, et\u00a0al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1\u2014a consensus overview. Hum Pathol. 2017;67:1\u201310.","journal-title":"Hum Pathol"},{"key":"2443_CR24","doi-asserted-by":"crossref","unstructured":"Pacot L, Vidaud D, Sabbagh A, Laurendeau I, Briand-Suleau A, Coustier A, et\u00a0al. Severe Phenotype in Patients with Large Deletions of NF1. Cancers. 2021;13(12).","DOI":"10.3390\/cancers13122963"},{"key":"2443_CR25","doi-asserted-by":"crossref","unstructured":"Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E, et\u00a0al. NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program. Cancers. 2019;11(5).","DOI":"10.3390\/cancers11050707"},{"key":"2443_CR26","unstructured":"Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection. Screening programme: Early detection of breast cancer. 2023. https:\/\/www.oesterreich.gv.at\/en\/themen\/gesundheit\/medizinische_versorgung\/screening-programm_brustkrebs-frueherkennung.html. Accessed 17 Jan 2024."},{"issue":"2","key":"2443_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11060-017-2517-6","volume":"134","author":"E Trevisson","year":"2017","unstructured":"Trevisson\u00a0E, Cassina\u00a0M, Opocher\u00a0E, Vicenzi\u00a0V, Lucchetta\u00a0M, Parrozzani\u00a0R, et\u00a0al. Natural history of optic pathway gliomas in a\u00a0cohort of unselected patients affected by Neurofibromatosis 1. J\u00a0Neurooncol. 2017;134(2):279\u201387.","journal-title":"J Neurooncol"},{"issue":"6","key":"2443_CR28","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/eye.2010.227","volume":"25","author":"DH Gutmann","year":"2011","unstructured":"Gutmann\u00a0DH, Listernick\u00a0R, Ferner\u00a0RE. Screening for symptomatic optic pathway glioma in children with neurofibromatosis type\u00a01. Eye. 2011;25(6):818.","journal-title":"Eye"},{"issue":"1","key":"2443_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-019-1067-8","volume":"14","author":"ML Armand","year":"2019","unstructured":"Armand\u00a0ML, Taieb\u00a0C, Bourgeois\u00a0A, Bourlier\u00a0M, Bennani\u00a0M, Bodemer\u00a0C, et\u00a0al. Burden of adult neurofibromatosis 1: development and validation of a\u00a0burden assessment tool. Orphanet J Rare Dis. 2019;14(1):94.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2443_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","volume":"12","author":"K Jett","year":"2010","unstructured":"Jett\u00a0K, Friedman\u00a0JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1\u201311.","journal-title":"Genet Med"},{"key":"2443_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00112-024-01955-3","author":"AA Azizi","year":"2024","unstructured":"Azizi\u00a0AA, Baumgartner\u00a0AC, Seidel\u00a0M, Zobel\u00a0J, Ebetsberger-Dachs\u00a0G, Zellner\u00a0H, et\u00a0al. Neurofibromatose Typ\u00a01: Vorsorgebogen f\u00fcr Kinder und Jugendliche in \u00d6sterreich. Monatsschrift Kinderheilkunde. 2024; https:\/\/doi.org\/10.1007\/s00112-024-01955-3.","journal-title":"Monatsschrift Kinderheilkunde"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02443-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02443-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02443-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T22:21:49Z","timestamp":1757110909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02443-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":31,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02443-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.\u00a0Azizi is member of advisory boards for Alexion and Novartis and has received lecture honoraria from Astra Zeneca and Alexion as well as\u00a0scientific grant and travel support by Alexion. A.-S.\u00a0Bergmeister-Berghoff has research support from Daiichi Sankyo, Roche and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa, Seagen, Alexion as well as travel support from Roche, Amgen and AbbVie. S.\u00a0Farschtschi has received speaker honoraria from Astra Zeneca and Alexion and compensation for advice or lecturing from Alexion not related to this study and is honorary chair of the German lay organization Bundesverband Neurofibromatose. R.\u00a0Gruber received medical fees for lectures and advisory boards from Lilly, Sanofi and Pfizer. M.\u00a0Hutterer has received honoraria for lectures, consultation or advisory board participation from Bristol-Meyers Squibb, Takeda, Eli Lilly and Gr\u00fcnenthal. C.\u00a0R\u00f6hl is a\u00a0member of advisory boards for Alexion and Boehringer Ingelheim and has received travel support and honoraria. V.\u00a0Sunder-Plassmann, V.\u00a0Ladurner and T.\u00a0Welponer declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}